Free shipping on all orders over $ 500

Vandortuzumab vedotin

Cat. No. M24699

All AbMole products are for research use only, cannot be used for human consumption.

Vandortuzumab vedotin Structure
Synonym:

DSTP 3086S; RG 7450; MSTP2109A

Size Price Availability
100ug USD 600 4-7 Days
1mg USD 1200 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.

Chemical Information
CAS Number 1471985-92-8
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Anthony Markham. Drugs. Tisotumab Vedotin: First Approval

[2] Emma D Deeks. Drugs. Disitamab Vedotin: First Approval

[3] Emma D Deeks. Drugs. Polatuzumab Vedotin: First Global Approval

[4] Carrie Van Der Weyden, et al. Expert Rev Hematol. Brentuximab vedotin in T-cell lymphoma

Related Antibody-Drug Conjugates (ADCs) Products
Talacotuzumab-MMAE

Talacotuzumab-MMAE is an antibody-drug conjugate (ADC) targeting IL-3Ra / CD123. Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody.

Enfortumab vedotin-ejfv

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate (ADC) for the management of urothelial carcinoma. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable maleimidocaproylvaline-citrulline linker.

Farletuzumab MMAE

Farletuzumab MMAE is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated to MMAE.

Zilovertamab vedotin

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.

Tisotumab Vedotin

Tisotumab Vedotin is a tissue factor-directed antibody-drug conjugate (ADC) containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethylmethane auristatin E (MMAE), which can be used in studies related to cervical cancer.

  Catalog
Abmole Inhibitor Catalog




Keywords: Vandortuzumab vedotin, DSTP 3086S; RG 7450; MSTP2109A supplier, Antibody-Drug Conjugates (ADCs), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.